Uprevstobart

尤若苏拜单抗

Report date: 2025/09/03 20:01:14

Base Information

Drug NameUprevstobart
Drug Alias NameINCA-00186INCA-0186
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of Action5'-nucleotidase inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
Targets5'-nucleotidase
Therapy Area/IndicationsSolid tumoursGastrointestinal NeoplasmsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIncyte Corp Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIncyte Corp
Active IndicationsN/A
Inactive IndicationsSolid tumoursGastrointestinal NeoplasmsSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeN/A
Related LinksN/A